Related Experiment Video
Updated: Aug 8, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Genotypic and Phenotypic Composition of Sickle Cell Disease in the Arab Population - A Systematic Review
Fateen Ata1, Alaa Rahhal2, Lujain Malkawi3
1Department of Endocrinology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Insights
This systematic review analyzes sickle cell disease (SCD) genetics in the Arabic population, finding common genotypes and complications. Current treatments are limited, with newer therapies like gene therapy not yet utilized.
Area of Science:
- Hematology
- Genetics
- Population Health
Background:
- Sickle cell disease (SCD) exhibits ethnic and regional variations in clinical presentation.
- Newer SCD therapies are emerging in Western populations but are not widely adopted in Arabic regions.
- Understanding regional genetic variations is crucial for predicting treatment efficacy.
Purpose of the Study:
- To systematically review and consolidate data on the genetic composition of SCD within the Arabic population.
- To identify common SCD genotypes and phenotypic manifestations in this demographic.
- To assess the current treatment landscape and the adoption of novel therapies.
Main Methods:
- A systematic review of 184 studies (including observational studies and clinical trials) from PubMed, Scopus, and Google Scholar.
- Data extraction for 44,034 patients, focusing on SCD genotypes, complications, and treatments.
- Analysis of genetic variations and clinical outcomes in the Arabic SCD population.
Main Results:
- The most prevalent SCD genotypes were Hb SS (77%), Hb Sβ0 (9.9%), and Hb Sβ+ (7.2%).
- Common complications included pain crises (48.25%), neurological issues (33.46%), and hepatobiliary problems (25.53%).
- Reported treatments were hydroxyurea (20%), blood transfusions (14.32%), and Deferasirox (3.03%), with no use of stem cell transplantation or newer agents noted.
Conclusions:
- This review provides a comprehensive overview of SCD genetic makeup and common complications in the Arabic population.
- Current treatment strategies in the region are limited, with a significant gap in the utilization of advanced therapies.
- Further research is needed to guide the implementation of genetic therapies and novel treatments for SCD in Arab countries.
Abstract:
Sickle cell disease (SCD) is a genetic disease influenced by ethnicity and regional differences in its clinical course. Recent advances in the management of SCD with newer therapies are being introduced to the Western population. However, many of these treatments are yet to be used in the Arabic SCD population. Understanding the genetic variations of SCD regionally is essential to anticipate the utilization of new treatments. This systematic review's main objective is to pool the available data on the genetic composition of SCD in the Arabic population. Data for 44,034 patients was extracted from 184 studies (11 case reports, 8 case series, 56 retrospectives, 107 prospective observational studies, and 2 clinical trials) using PubMed, Scopus, and Google Scholar. Male (49%) and female (51%) patients were equally reported wherever gender was available (N=13105). Various SCD genotypes were reported in a total of 14,257 patients, including Hb SS (77%) Hb Sβ0 (9.9%), and Hb Sβ+ (7.2%), while the rest of the genotypes, including HbSC, HbSD, HbSE, HbSO Arab, Hb S/α-Thal, Hb Sβ0 + α-Thal, and HBS Oman were individually reported in <4% of the cases. Major SCD complications in the Arab population included pain crises (48.25%) followed by neurological complications (33.46%), hepatobiliary complications (25.53%), musculoskeletal complications (24.73%), and hemolytic anemia (23.57%). The treatments reported for SCD included hydroxyurea (20%), blood transfusion (14.32%), and Deferasirox (3.03%). We did not find the use of stem cell transplantation or newer treatments such as L-Glutamine, Voxelotor, Crizanlizumab, or gene therapy reported in any of the studies included in our review. This review highlights the genetic makeup of SCD in Arab countries and its common phenotypic manifestations and will help direct further research on SCD in this region, especially concerning genetic therapy.
Systematic Review Registration:
The protocol has been registered in the International Prospective Register of Systematic Reviews(PROSPERO):CRD42020218,666. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=218666.
Related Concept Videos
Multiple Allele Traits
Genetic Variation
Genes exist in different versions called alleles,...
Genetic Lingo
Pedigree Analysis
Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
Incomplete Dominance

